XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.3
Equity - Narrative (Details)
 9 Months Ended
Dec. 31, 2023
USD ($)
shares
Sep. 30, 2024
USD ($)
property
$ / shares
shares
Sep. 30, 2023
USD ($)
shares
Aug. 31, 2022
shares
Equity [Line Items]        
Authorized amount (in shares) | shares       10,000,000
Common shares repurchased (in shares) | shares   0 0  
Shares remaining available for repurchase (in shares) | shares   6,874,241    
Unsettled repurchases   $ 0    
Series C cumulative convertible preferred, shares outstanding (in shares) | shares 1,935,400 1,935,400    
Series C cumulative convertible preferred, liquidation preference $ 96,770,000 $ 96,770,000    
OP unit equivalent in common shares   1.13    
Partners capital account, shares issued for units redeemed | shares 822,627   9,944  
Partners' capital account, exchanges and conversions $ 7,800,000   $ 49,000  
Exchange ratio of partner units (in shares) 1.13      
Purchase of noncontrolling interest in consolidated joint venture   $ 27,898,000    
Additional Paid-in-Capital        
Equity [Line Items]        
Purchase of noncontrolling interest in consolidated joint venture   $ 23,843,000    
Warehouse / Distribution Facility        
Equity [Line Items]        
Number of properties | property   2    
Purchase of remaining equity   $ 27,873,000    
Series C Cumulative Convertible Preferred Stock        
Equity [Line Items]        
Series C cumulative convertible preferred, shares outstanding (in shares) | shares   1,935,400    
Preferred stock, dividend per annum (in dollars per share) | $ / shares   $ 3.25    
Series C cumulative convertible preferred, liquidation preference   $ 96,770,000    
Convertible preferred stock, conversion ratio (in shares) | shares   2.4339    
Preferred stock conversion, threshold conversion price percentage (at least)   1.25    
Trustee        
Equity [Line Items]        
Shares granted (in shares) | shares   76,215 70,072  
Grant date fair value   $ 675,000 $ 714,000  
Share-Based Payment Arrangement | Nontrustee        
Equity [Line Items]        
Shares granted (in shares) | shares   150,000    
Grant date fair value   $ 1,545,000    
Vesting period   28 months    
At-The-Market Program        
Equity [Line Items]        
Sale of stock, authorized amount (up to)   $ 350,000,000